Literature DB >> 2491832

Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity.

J W Mellors1, R J Debs, J L Ryan.   

Abstract

In this study we compared the ability of free- and liposome-incorporated murine recombinant gamma interferon (rIFN-gamma) to enhance peritoneal macrophage H2O2 release and antitoxoplasma activity in vitro. rIFN-gamma was efficiently (37 to 47%) incorporated into multilamellar vesicles composed of phosphatidylglycerol/cholesterol in a 2:1 molar ratio. The amount of rIFN-gamma incorporated into multilamellar vesicles and added to macrophages (0.1 to 1,000 U/ml) was quantitated with [3H]rIFN-gamma. The concentration of liposomal rIFN-gamma required to enhance macrophage H2O2 release (1 U/ml) and maximally inhibit Toxoplasma gondii growth (10 U/ml) was one-tenth the concentration required for free rIFN-gamma (10 and 100 U/ml, respectively). This increase in potency was observed in both thioglycolate-elicited and resident peritoneal macrophages. Control liposomes containing encapsulated buffer had no effect on the potency of free rIFN-gamma. The duration of macrophage activation induced by 24 h of liposomal rIFN-gamma treatment was also considerably longer than that induced by free rIFN-gamma (2 days versus less than 1 day). These data indicate that liposomal rIFN-gamma is more active than free rIFN-gamma as an inducer of macrophage microbicidal properties in vitro. This enhanced activity, combined with the potential for selective delivery of liposomal rIFN-gamma to phagocytic cells in vivo, may improve the therapeutic efficacy of rIFN-gamma in infections characterized by parasitization of phagocytes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491832      PMCID: PMC313054          DOI: 10.1128/iai.57.1.132-137.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  Specific labeling of intracellular Toxoplasma gondii with uracil.

Authors:  E R Pfefferkorn; L C Pfefferkorn
Journal:  J Protozool       Date:  1977-08

3.  Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide.

Authors:  W C Koff; S D Showalter; B Hampar; I J Fidler
Journal:  Science       Date:  1985-04-26       Impact factor: 47.728

4.  Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.

Authors:  S Vadhan-Raj; C F Nathan; S A Sherwin; H F Oettgen; S E Krown
Journal:  Cancer Treat Rep       Date:  1986-05

5.  Phase I trial of recombinant interferon gamma in cancer patients.

Authors:  S Vadhan-Raj; A Al-Katib; R Bhalla; L Pelus; C F Nathan; S A Sherwin; H F Oettgen; S E Krown
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

6.  In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.

Authors:  S D Sharma; J M Hofflin; J S Remington
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

7.  Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor.

Authors:  D A Eppstein; Y V Marsh; M van der Pas; P L Felgner; A B Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon.

Authors:  W C Koff; W E Fogler; J Gutterman; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.

Authors:  I J Fidler; W E Fogler; E S Kleinerman; I Saiki
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

10.  Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients.

Authors:  B A Navia; C K Petito; J W Gold; E S Cho; B D Jordan; R W Price
Journal:  Ann Neurol       Date:  1986-03       Impact factor: 10.422

View more
  6 in total

Review 1.  Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.

Authors:  João Paulo Assolini; Virginia Márcia Concato; Manoela Daiele Gonçalves; Amanda Cristina Machado Carloto; Ivete Conchon-Costa; Wander Rogério Pavanelli; Francine Nesello Melanda; Idessania Nazareth Costa
Journal:  Parasitol Res       Date:  2017-05-05       Impact factor: 2.289

Review 2.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

3.  Respiratory burst capacity of activated macrophages is resistant to depression by erythrocyte phagocytosis.

Authors:  M G Schwacha; D J Loegering
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

Review 4.  Role of gamma interferon in Toxoplasma gondii infection.

Authors:  C S Subauste; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

5.  Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant.

Authors:  E R Pfefferkorn; R F Nothnagel; S E Borotz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

6.  Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin.

Authors:  E R Pfefferkorn; S E Borotz
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.